Compare Incyte Corporation (INCY) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Reddit Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Reddit Inc trades at $153.3 (market cap $30.05B). The key difference: Reddit Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Reddit Inc nearer its low. Which is the better fit depends on your goals.
| INCY | RDDT | |
|---|---|---|
Market Cap | $24.54B | $30.05B |
Sector | Health | Media |
52-Week High | $129.93 | $270.71 |
52-Week Low | $81.61 | $121.84 |
Enterprise Value | $20.04B | $27.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Reddit (RDDT) trades at $153.46, down 3.3% in the past 24 hours amid bearish technical signals. The company demonstrates strong fundamentals with 61% YoY revenue growth in Q2 2026 and consistent earnings beats, though recent CEO share sales and search traffic concerns have pressured the stock. Technical indicators show resistance at $160 with support at $154, while fundamentals reveal robust profitability with 91.44% gross margins and 31.35% net income margins.
Despite near-term volatility, Reddit's growth trajectory and AI integration opportunities support long-term upside potential. The consensus price target of $220.25 implies 43% upside, though risks include user growth sustainability and competitive pressures. With no sell ratings from 28 covering analysts and strong institutional interest, the stock presents a compelling growth opportunity for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
